Trade Regeneron Pharmaceuticals, Inc. - REGN CFD

Add to favourite

893.34

0.28%

3.55

Low: 890.95

High: 903.16

Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

3.55

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Regeneron Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	890.85
Open*	901.34
1-Year Change*	11.63%
Day's Range*	890.95 - 903.16
52 wk Range	684.81-943.00
Average Volume (10 days)	553.18K
Average Volume (3 months)	11.53M
Market Cap	101.32B
P/E Ratio	26.53
Shares Outstanding	108.95M
Revenue	13.10B
EPS	35.05
Dividend (Yield %)	N/A
Beta	0.10
Next Earnings Date	Feb 2, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 18, 2024	890.85	-10.19	-1.13%	901.04	905.64	889.35
Apr 17, 2024	900.87	2.26	0.25%	898.61	911.55	896.73
Apr 16, 2024	891.70	-1.09	-0.12%	892.79	899.50	888.57
Apr 15, 2024	898.14	-15.39	-1.68%	913.53	919.67	893.74
Apr 12, 2024	903.56	-7.29	-0.80%	910.85	912.08	896.37
Apr 11, 2024	919.49	-7.44	-0.80%	926.93	928.26	905.33
Apr 10, 2024	935.29	4.62	0.50%	930.67	937.52	919.29
Apr 9, 2024	942.94	6.75	0.72%	936.19	948.81	936.07
Apr 8, 2024	938.30	1.48	0.16%	936.82	942.46	929.12
Apr 5, 2024	940.03	2.13	0.23%	937.90	948.85	931.34
Apr 4, 2024	935.83	-23.91	-2.49%	959.74	961.70	932.70
Apr 3, 2024	950.59	-2.36	-0.25%	952.95	960.58	949.95
Apr 2, 2024	954.62	-6.72	-0.70%	961.34	961.34	949.27
Apr 1, 2024	967.84	5.24	0.54%	962.60	969.67	949.69
Mar 28, 2024	960.18	-6.27	-0.65%	966.45	968.07	956.79
Mar 27, 2024	965.92	0.97	0.10%	964.95	975.08	961.26
Mar 26, 2024	962.91	7.47	0.78%	955.44	966.58	955.34
Mar 25, 2024	957.68	11.53	1.22%	946.15	963.27	940.61
Mar 22, 2024	966.43	0.47	0.05%	965.96	974.86	957.84
Mar 21, 2024	967.81	2.31	0.24%	965.50	978.72	965.07

Regeneron Pharmaceuticals, Inc. Events

Time (UTC)	Country	Event
Thursday, May 2, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Regeneron Pharmaceuticals Inc Earnings Call Q1 2024 Regeneron Pharmaceuticals Inc Earnings Call Forecast - Previous -
Time (UTC) 12:30	Country US	Event Q1 2024 Regeneron Pharmaceuticals Inc Earnings Release Q1 2024 Regeneron Pharmaceuticals Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 14:30	Country US	Event Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Forecast - Previous -
Friday, June 14, 2024
Time (UTC) 14:30	Country US	Event Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Regeneron Pharmaceuticals Inc Annual Shareholders Meeting Forecast - Previous -
Thursday, August 1, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Regeneron Pharmaceuticals Inc Earnings Release Q2 2024 Regeneron Pharmaceuticals Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	12172.9	16071.7	8497.1	7863.4	6710.8
Revenue	12172.9	16071.7	8497.1	7863.4	6710.8
Cost of Revenue, Total	1560.4	2437.5	1119.9	782.2	434.1
Gross Profit	10612.5	13634.2	7377.2	7081.2	6276.7
Total Operating Expense	7434	7124.9	4920.5	5653.6	4176.4
Selling/General/Admin. Expenses, Total	2115.9	1824.9	1346	1834.8	1556.2
Research & Development	3592.5	2908.1	2735	3036.6	2186.1
Operating Income	4738.9	8946.8	3576.6	2209.8	2534.4
Interest Income (Expense), Net Non-Operating	-19.6	328.8	139.1	88.1	13.7
Other, Net	139.5	50.2	94.7	131.2	5.4
Net Income Before Taxes	4858.8	9325.8	3810.4	2429.1	2553.5
Net Income After Taxes	4338.4	8075.3	3513.2	2115.8	2376.4
Net Income Before Extra. Items	4338.4	8075.3	3513.2	2115.8	2376.4
Net Income	4338.4	8075.3	3513.2	2115.8	2444.4
Income Available to Common Excl. Extra. Items	4338.4	8075.3	3513.2	2115.8	2376.4
Income Available to Common Incl. Extra. Items	4338.4	8075.3	3513.2	2115.8	2444.4
Dilution Adjustment
Diluted Net Income	4338.4	8075.3	3513.2	2115.8	2444.4
Diluted Weighted Average Shares	113.5	112.2	115.1	114.6	114.8
Diluted EPS Excluding Extraordinary Items	38.2238	71.9724	30.523	18.4625	20.7003
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	40.4714	71.9724	30.523	18.4625	20.7003
Total Extraordinary Items					68
Other Operating Expenses, Total	-89.9	-45.6	-280.4
Unusual Expense (Income)	255.1

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	3158.1	3162.1	3414.4	2936.2	2857.2
Revenue	3158.1	3162.1	3414.4	2936.2	2857.2
Cost of Revenue, Total	404.9	457.5	540.6	317.8	297.1
Gross Profit	2753.2	2704.6	2873.8	2618.4	2560.1
Total Operating Expense	2141.6	2215.4	2267.6	1712.5	1747.3
Selling/General/Admin. Expenses, Total	652	601.1	660.5	529.1	476.3
Research & Development	1085.3	1101.2	1043.1	911.3	794.3
Other Operating Expenses, Total	-0.6	-0.5	-6.6	-45.7	-17.4
Operating Income	1016.5	946.7	1146.8	1223.7	1109.9
Interest Income (Expense), Net Non-Operating	68.5	-87.5	143	239	-176.8
Other, Net	-2.1	-1.2	34.9	47.1	30.1
Net Income Before Taxes	1082.9	858	1324.7	1509.8	963.2
Net Income After Taxes	968.4	817.8	1197.1	1315.7	852.1
Net Income Before Extra. Items	968.4	817.8	1197.1	1315.7	852.1
Net Income	968.4	817.8	1197.1	1315.7	852.1
Income Available to Common Excl. Extra. Items	968.4	817.8	1197.1	1315.7	852.1
Income Available to Common Incl. Extra. Items	968.4	817.8	1197.1	1315.7	852.1
Diluted Net Income	968.4	817.8	1197.1	1315.7	852.1
Diluted Weighted Average Shares	113.9	114	114.1	112.8	114
Diluted EPS Excluding Extraordinary Items	8.50219	7.17368	10.4917	11.664	7.47456
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	8.50219	7.66579	10.7546	11.664	9.20263
Unusual Expense (Income)	0	56.1	30	0	197

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	15884.1	14014.9	9779.1	7689.1	6447.6
Cash and Short Term Investments	7742.3	5694.7	3587	3214.3	2809.9
Cash & Equivalents	3105.9	2885.6	2193.7	1617.8	1467.7
Short Term Investments	4636.4	2809.1	1393.3	1596.5	1342.2
Total Receivables, Net	5328.7	6036.5	4114.7	2672.2	2243.2
Accounts Receivable - Trade, Net	5328.7	6036.5	4114.7	2672.2	2243.2
Total Inventory	2401.9	1951.3	1916.6	1415.5	1151.2
Prepaid Expenses	411.2	332.4	160.8	387.1	243.3
Other Current Assets, Total
Total Assets	29214.5	25434.8	17163.3	14805.2	11734.5
Property/Plant/Equipment, Total - Net	3763	3482.2	3221.6	2890.4	2575.8
Property/Plant/Equipment, Total - Gross	5432.2	4880.3	4352.7	3812.8	3304.5
Accumulated Depreciation, Total	-1669.2	-1398.1	-1131.1	-922.4	-728.7
Long Term Investments	6640.1	6878	3194.8	3312.4	1800.5
Other Long Term Assets, Total	2011.8	1059.7	967.8	913.3	910.6
Total Current Liabilities	3141.3	3932.5	2697.4	2096.6	1442.8
Accounts Payable	589.2	564	475.5	418.1	218.2
Accrued Expenses	2073.9	1880.5	1502.3	1037.4	751.3
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0	719.7
Other Current Liabilities, Total	478.2	768.3	719.6	641.1	473.3
Total Liabilities	6550.5	6666	6138	3715.5	2977.2
Total Long Term Debt	2701.4	1980	2695.7	713.9	708.5
Capital Lease Obligations	720	0	717.2	713.9	708.5
Other Liabilities, Total	707.8	753.5	744.9	905	825.9
Total Equity	22664	18768.8	11025.3	11089.7	8757.3
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.1	0.1	0.1	0.1	0.1
Additional Paid-In Capital	9949.3	8087.5	6716.2	4428.6	3911.6
Retained Earnings (Accumulated Deficit)	23306.7	18968.3	10893	7379.8	5254.3
Treasury Stock - Common	-10353.3	-8260.9	-6613.3	-739.9	-396.4
Other Equity, Total	-238.8	-26.2	29.3	21.1	-12.3
Total Liabilities & Shareholders’ Equity	29214.5	25434.8	17163.3	14805.2	11734.5
Total Common Shares Outstanding	109.6	108.675	106.951	110.277	109.006
Long Term Debt	1981.4	1980	1978.5
Intangibles, Net	915.5

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	18634.8	16923	16909.2	15884.1	15428.6
Cash and Short Term Investments	9913.6	8927.7	8959.7	7742.3	7021.7
Cash & Equivalents	2152.3	1937.2	3916.3	3105.9	3491.3
Short Term Investments	7761.3	6990.5	5043.4	4636.4	3530.4
Total Receivables, Net	5584.5	5121.3	5118.6	5328.7	5548.3
Accounts Receivable - Trade, Net	5584.5	5121.3	5118.6	5328.7	5548.3
Total Inventory	2562	2507.7	2424.7	2401.9	2412.2
Prepaid Expenses	574.7	360.8	406.2	411.2	446.4
Other Current Assets, Total		5.5
Total Assets	32163.3	30657.5	30059.9	29214.5	27677.8
Property/Plant/Equipment, Total - Net	4006.1	3922.6	3880.9	3763	3704.2
Long Term Investments	5839.3	6405.5	6114.9	6640.1	6016.9
Other Long Term Assets, Total	2665.9	2453.4	2226.2	2011.8	1724
Total Current Liabilities	3598.6	3104.4	3100.1	3141.3	2879.2
Accounts Payable	536.6	547.3	599.5	589.2	535.6
Accrued Expenses	2644.7	2176	2074.3	2074.2	1796.4
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases				0	0
Other Current Liabilities, Total	417.3	381.1	426.3	477.9	547.2
Total Liabilities	7258.9	6639.6	6564.7	6550.5	6239
Total Long Term Debt	2702.6	2702.2	2701.8	2701.4	2701.1
Long Term Debt	1982.6	1982.2	1981.8	1981.4	1981.1
Capital Lease Obligations	720	720	720	720	720
Other Liabilities, Total	957.7	833	762.8	707.8	658.7
Total Equity	24904.4	24017.9	23495.2	22664	21438.8
Preferred Stock - Non Redeemable, Net	0	0	0	0	0
Common Stock	0.1018	0.1018	0.1018	0.1	0.1
Additional Paid-In Capital	11251.5	10888.5	10597.7	9949.3	9518.2
Retained Earnings (Accumulated Deficit)	26100.7	25092.9	24124.5	23306.7	22109.6
Treasury Stock - Common	-12271.1	-11765.9	-11045.5	-10353.3	-9914
Other Equity, Total	-176.802	-197.702	-181.602	-238.8	-275.1
Total Liabilities & Shareholders’ Equity	32163.3	30657.5	30059.9	29214.5	27677.8
Total Common Shares Outstanding	108.8	108.9	109.7	109.6	108.8
Intangibles, Net	1017.2	953	928.7	915.5	804.1

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	4338.4	8075.3	3513.2	2115.8	2444.4
Cash From Operating Activities	5014.9	7081.3	2618.1	2430	2195.1
Cash From Operating Activities	341.4	286.2	235.9	210.3	148.2
Deferred Taxes	-746.4	-147.1	75.6	-130.6	-140
Non-Cash Items	1324.8	783.4	297	435	439.5
Cash Taxes Paid	1502.4	1218.4	188.1	342.3	205.6
Cash Interest Paid	53.7	55.8	23.2	25	22.3
Changes in Working Capital	-243.3	-1916.5	-1503.6	-200.5	-697
Cash From Investing Activities	-3784.6	-5384.7	-70.6	-2027.8	-1463
Capital Expenditures	-1616.9	-551.9	-614.6	-429.6	-383.1
Other Investing Cash Flow Items, Total	-2167.7	-4832.8	544	-1598.2	-1079.9
Cash From Financing Activities	-1009	-1005.8	-1970.5	-252.1	-77.1
Financing Cash Flow Items	-445.7	-1032.7	-680.8	-188	-187.2
Issuance (Retirement) of Stock, Net	-563.3	26.9	-3271.6	-64.1	110.1
Issuance (Retirement) of Debt, Net	0	0	1981.9		0
Net Change in Cash	221.3	690.8	577	150.1	655

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	817.8	4338.4	3141.3	1825.6	973.5
Cash From Operating Activities	1367.6	5014.9	3295	2666.1	2101.7
Cash From Operating Activities	99.5	341.4	241.3	148.7	74.3
Deferred Taxes	-216.5	-746.4	-466.7	-381	-225
Non-Cash Items	425.9	1324.8	1004.4	1030.9	455.7
Changes in Working Capital	240.9	-243.3	-625.3	41.9	823.2
Cash From Investing Activities	-235.7	-3784.6	-1926.9	-2119.2	-1705.3
Capital Expenditures	-279.1	-1616.9	-1364.7	-295.4	-141.8
Other Investing Cash Flow Items, Total	43.4	-2167.7	-562.2	-1823.8	-1563.5
Cash From Financing Activities	-322.5	-1009	-761.4	-36.4	64.7
Financing Cash Flow Items	-97	-445.7	-256.6	-147.7	-98.8
Issuance (Retirement) of Stock, Net	-225.5	-563.3	-504.8	111.3	163.5
Net Change in Cash	809.4	221.3	606.7	510.5	461.1
Issuance (Retirement) of Debt, Net		0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Regeneron Company profile

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Industry:

Bio Therapeutic Drugs

777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024